Mark Bear, Ph.D., Scientific Founder
Dr. Bear is the Picower Professor of Neuroscience, Picower Center for Learning and Memory, at MIT. He was previously the Sidney A. and Dorothea Doctors Fox Professor of Neuroscience at Brown. Dr. Bear is world renowned for his research on the mechanisms of experience-dependent cortical plasticity. Dr. Bear was a founder of Sention and served as Chair of Sention's SAB from 1999-2005. He received the Society for Neuroscience Young Investigator Award in 1993, has been an Investigator of the Howard Hughes Medical Institute since 1994, and was elected as a Fellow of the American Association for the Advancement of Science in 2003 and the American Academy of Arts and Sciences in 2004.

Randall Carpenter, M.D., Co-Founder, President and Chief Executive Officer
Dr. Carpenter joined Seaside Therapeutics from Sention where he was President and CEO from September 2001 through April 2005. Dr. Carpenter was previously Vice-President of Clinical Research & Development and Regulatory Affairs from 1998-2001 at Adolor Corporation. Prior to Adolor, Dr. Carpenter was Director of Clinical Research at Astra Pain Control and Astra USA and a member of the Global Therapeutic Area Team. Prior to joining industry, Dr. Carpenter spent 15 years in academic medicine.

Timothy Ocain, Ph.D., Senior Vice President, Research and Development

Dr. Ocain has over twenty years experience in the pharmaceutical and biotechnology industry and will share responsibility for advancing compounds through preclinical development and first-in-human studies. Dr. Ocain joins Seaside from Millennium Pharmaceuticals, where he held several leadership positions over his eight year tenure, most recently heading up the Inflammation Disease Group.  While at Millennium, Dr. Ocain directed all pharmacology, cellular immunology, and biochemistry efforts in the Inflammation area, playing a principal role in the delivery of multiple compounds suitable for clinical development.  Dr. Ocain has held senior drug discovery positions with extensive project management responsibilities in the biotech sector as well as in large pharmaceutical companies.  Prior to joining Millennium he spent six years at Procept, Inc, where he served as Vice President, Chemistry and Structural Biology.  His background also includes seven years at Wyeth-Ayerst Research engaged in Cardiovascular, CNS, and Immunology drug discovery. Dr. Ocain earned his PhD in Pharmaceutical Chemistry from the University of Wisconsin-Madison, followed by post-doctoral research at the University of Minnesota.

Kazumi Shiosaki, Ph.D., Co-Founder and Scientific Advisor
Dr. Shiosaki joined Seaside Therapeutics from Sention where she was acting Chief Scientific Officer from January 2003 through April 2005. Dr. Shiosaki was formerly Senior Vice President of Drug Discovery and Scientific Development at Millennium Pharmaceuticals and she is also currently a Venture Partner at MPM Capital. Dr. Shiosaki's experience in the pharmaceutical and biotechnology industry includes CNS , cardiovascular and anti-viral drug discovery at Abbott Laboratories and her role in building Millennium's drug discovery organization. Dr. Shiosaki received her Ph.D. in Chemistry from U.C. Berkeley.

Stephen Warren, Ph.D., Chair, Scientific Advisory Board
Dr. Warren is the William Patterson Timmie Professor and Chairman of Human Genetics as well as Professor of Biochemistry and of Pediatrics at Emory University School of Medicine. Dr. Warren is world renowned for his research on the genetics of mental retardation and led the international team that identified the FMR1 (Fragile X mental retardation 1) gene, which is responsible for fragile X syndrome. Dr. Warren is president-elect of the American Society of Human Genetics and was Editor-in-Chief of The American Journal of Human Genetics from 1999 - 2005. Among his awards are the William Rosen Research Award from the National Fragile X Foundation, a MERIT award from the National Institute of Health and the William Allan Award from the American Society of Human Genetics. In 2003, he was inducted into the National Institute of Child Health and Human Development's Hall of Honor and in 2004, Dr. Warren was elected to the Institute of Medicine of the National Academies.

Next: Strategy »